---
title: BiPER Therapeutics
---

[![logo](https://biper-tx.com/hubfs/Home/logo.png)](https://biper-tx.com/?hsLang=en)

- [Science & Technology](https://biper-tx.com/science?hsLang=en)
- [Pipeline](https://biper-tx.com/science?hsLang=en#pipeline)
- [Investors & Partnership](https://biper-tx.com/investors?hsLang=en)
- [Company](https://biper-tx.com/about?hsLang=en)

[Contact us](https://biper-tx.com/?hsLang=en#contact)

[Contact us](https://biper-tx.com/?hsLang=en#contact)

 Innovating Cancer Care

# A new class of selective oral drugs overstressing pathological cells to cure patients

BiPER Therapeutics develops first-in-class selective BiP inhibitors as targeted therapy with a first focus on treating cancers patients

[Our Technology](https://biper-tx.com/science?hsLang=en)

![intersect](https://biper-tx.com/hubfs/Home/intersect.png)

![science](https://biper-tx.com/hubfs/Home/science.png)

![logo-small](https://biper-tx.com/hubfs/Home/logo-small.png)Science & Technology

## First-in-class selective BiP inhibitors to treat cancers and beyond

BPR001-615 is first-in-class, highly selective, orally bioavailable, targeted therapy designed to treat the > 50% of BiP High patients through a precision medicine approach across multiple indications

[Know more](https://biper-tx.com/science?hsLang=en)

![logo-small](https://biper-tx.com/hubfs/Home/logo-small.png)About

## About BiPER Therapeutics

BiPER ‘s name summarizes the original and unique approach of our Lead candidate targeting BiP and leading to cancer cell death through unresolved ER (Endoplasmic Reticulum) Stress induction

BIPER Therapeutics primary focus is to treat cancer patients by pushing cancer cells to burn out. We are advancing a first pipeline of first-in-class small molecules that induce unresolved ER stress in cancer cells and strentengh non-cancer cells to change the course of disease and change patients' life

[Know more](https://biper-tx.com/about?hsLang=en)

![about](https://biper-tx.com/hubfs/Home/about.png)

Patients Supported in Care

## Pipeline

Our pipeline highlights three first-in-class candidates advancing through early-stage development toward clinical validation.

[Know more](https://biper-tx.com/science?hsLang=en#pipeline)

Candidate Indication

Lead Selection

IND Enabling

Phase 1/2a

Phase 2b

BPR001-615 Gastro Intestinal Cancer

BPR002 Solid Tumors

BPR003 Non-oncology Undisclosed

![Investors](https://biper-tx.com/hubfs/Home/Investors.png)

![logo-small](https://biper-tx.com/hubfs/Home/logo-small.png)Investors & Partnership

## Partner with Innovation

BiPER Therapeutics seeks collaboration with pharmaceutical leaders and investors to accelerate the clinical development of our first-in-class BiP inhibitors and redefine the standard of care.

[Know more](https://biper-tx.com/investors?hsLang=en)

Collaborating with premier scientific pioneers to define the next generation of cancer care

![partner1](https://biper-tx.com/hubfs/Home/Partners/partner1.png)

![partner2](https://biper-tx.com/hubfs/Home/Partners/partner2.png)

![partner3](https://biper-tx.com/hubfs/Home/Partners/partner3.png)

![partner4](https://biper-tx.com/hubfs/Home/Partners/partner4.png)

![partner5](https://biper-tx.com/hubfs/Home/Partners/partner5.png)

![partner6](https://biper-tx.com/hubfs/Home/Partners/partner6.png)

![partner7](https://biper-tx.com/hubfs/Home/Partners/partner7.png)

![logo-small](https://biper-tx.com/hubfs/Home/logo-small.png)Contact

## Get in Touch

Whether you are an investor, potential partner, or researcher, reach out to explore how we can collaborate to bring these life-saving therapies to patients.

![logo](https://biper-tx.com/hubfs/Home/logo.png)

- [Science & Technology](https://biper-tx.com/science?hsLang=en)
- [Pipeline](https://biper-tx.com/science?hsLang=en#pipeline)
- [Investors & Partnership](https://biper-tx.com/investors?hsLang=en)
- [Company](https://biper-tx.com/about?hsLang=en)

[Contact us](https://biper-tx.com/?hsLang=en#contact)

BiPER Therapeutics 32 Allée de la Robertsau 67000 Strasbourg

|

Copyright © BiPER Therapeutics 2026

|

[Legal Notice](https://biper-tx.com/notice?hsLang=en) 

[Follow us on LinkedIn](https://www.linkedin.com/company/biper-therapeutics/posts/?feedView=all)